The addition of tofacitinib to rheumatoid arthritis treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs, according to a study published in the Aug. 20 issue of the Annals of Internal Medicine.
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. 20 issue of the Annals of Internal Medicine.
Joel Kremer, M.D., from Albany Medical College in New York, and colleagues conducted a one-year trial of tofacitinib in 792 patients with active RA despite non-biologic DMARD therapy seen at 114 centers in 19 countries. Patients were randomly assigned in a 4:4:1:1 ratio to oral tofacitinib (5 or 10 mg twice daily) or placebo advanced to tofacitinib (5 or 10 mg twice daily). Improvement was determined using American College of Rheumatology (ACR20) criteria; Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4 [ESR]) of less than 2.6; DAS28-4(ESR)-defined remission; and change in Health Assessment Questionnaire Disability Index (HAQ-DI) score.
The researchers found that, for the 5-mg and 10-mg tofacitinib groups, the mean treatment differences by ACR20 criteria compared with the combined placebo groups were 21.2 and 25.8 percent, respectively. The tofacitinib groups also had superior HAQ-DI scores (month three) and DAS28-4(ESR) less than 2.6 response rates (month six) compared to placebo. For patients receiving 5-mg tofacitinib, 10-mg tofacitinib, and placebo, the incidence rates of serious adverse events were 6.9, 7.3, and 10.9 events per 100 patient-years of exposure, respectively. Additionally, in the tofacitinib groups, neutrophil counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, and serum creatinine levels had small increases.
"Tofacitinib improved disease control in patients with active RA despite treatment with non-biologic DMARDs, primarily methotrexate," the authors write.
This study was funded by Pfizer, the manufacturer of tofacitinib.
Explore further: Newly approved oral medication slows rheumatoid arthritis joint damage
More information: Full Text (subscription or payment may be required)
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Newly approved oral medication slows rheumatoid arthritis joint damage
Jan 24, 2013
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...
US study shows that tofacitinib is an efficacious treatment for active RA
May 25, 2011
Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent ...
Study shows efficacy of new rheumatoid arthritis drug
Aug 09, 2012
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England ...
EULAR issues updated rheumatoid arthritis management recommendations
Jul 03, 2013
The European League Against Rheumatism (EULAR) has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs (DMARDs) should be initiated ...
Pfizer says patient died in oral RA drug study
Apr 22, 2011
(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.
Recommended for you
Lateral wedge insoles not associated with improvement of knee pain in osteoarthritis
Aug 20, 2013
Although a pooling of data from 12 studies showed a statistically significant association between use of lateral wedge insoles and lower pain in medial knee osteoarthritis, among trials comparing wedge insoles with neutral ...
New rheumatoid arthritis treatment moves a step closer to reality
Aug 15, 2013
A new rheumatoid arthritis treatment has moved a step closer to reality with the announcement of collaboration between a University of Queensland start-up company and a major pharmaceutical firm.
Eating fish cuts risk of rheumatoid arthritis in women
Aug 13, 2013
(HealthDay)—Regular consumption of dietary long-chain n-3 polyunsaturated fatty acids (PUFAs) in fish is associated with reduced risk of rheumatoid arthritis (RA) in women, according to research published ...
Rheumatoid arthritis heightens risk of dangerous leg and lung blood clots
Aug 07, 2013
Rheumatoid arthritis significantly increases the risk of potentially fatal blood clots in the legs and lungs, reveals a large nationwide study published online in the Annals of the Rheumatic Diseases.
Prolactin reduces arthritis inflammation
Aug 01, 2013
Inflammatory joint diseases such as rheumatoid arthritis are the result of cartilage damage and loss. Chondrocytes are the only cells that are found in cartilage and their death is linked to decreased cartilage health.
Premature aging of immune cells in joints of kids with chronic arthritis
Jul 29, 2013
The joints of children with the most common form of chronic inflammatory arthritis contain immune cells that resemble those of 90-year-olds, according to a new study led by researchers at Children's Hospital of Pittsburgh ...
User comments
© Medical Xpress 2011-2013, Phys.org network
The addition of tofacitinib to rheumatoid arthritis treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs, according to a study published in the Aug. 20 issue of the Annals of Internal Medicine.
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. 20 issue of the Annals of Internal Medicine.
Joel Kremer, M.D., from Albany Medical College in New York, and colleagues conducted a one-year trial of tofacitinib in 792 patients with active RA despite non-biologic DMARD therapy seen at 114 centers in 19 countries. Patients were randomly assigned in a 4:4:1:1 ratio to oral tofacitinib (5 or 10 mg twice daily) or placebo advanced to tofacitinib (5 or 10 mg twice daily). Improvement was determined using American College of Rheumatology (ACR20) criteria; Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4 [ESR]) of less than 2.6; DAS28-4(ESR)-defined remission; and change in Health Assessment Questionnaire Disability Index (HAQ-DI) score.
The researchers found that, for the 5-mg and 10-mg tofacitinib groups, the mean treatment differences by ACR20 criteria compared with the combined placebo groups were 21.2 and 25.8 percent, respectively. The tofacitinib groups also had superior HAQ-DI scores (month three) and DAS28-4(ESR) less than 2.6 response rates (month six) compared to placebo. For patients receiving 5-mg tofacitinib, 10-mg tofacitinib, and placebo, the incidence rates of serious adverse events were 6.9, 7.3, and 10.9 events per 100 patient-years of exposure, respectively. Additionally, in the tofacitinib groups, neutrophil counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, and serum creatinine levels had small increases.
"Tofacitinib improved disease control in patients with active RA despite treatment with non-biologic DMARDs, primarily methotrexate," the authors write.
This study was funded by Pfizer, the manufacturer of tofacitinib.
Explore further: Newly approved oral medication slows rheumatoid arthritis joint damage
More information: Full Text (subscription or payment may be required)
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Newly approved oral medication slows rheumatoid arthritis joint damage
Jan 24, 2013
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...
US study shows that tofacitinib is an efficacious treatment for active RA
May 25, 2011
Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent ...
Study shows efficacy of new rheumatoid arthritis drug
Aug 09, 2012
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England ...
EULAR issues updated rheumatoid arthritis management recommendations
Jul 03, 2013
The European League Against Rheumatism (EULAR) has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs (DMARDs) should be initiated ...
Pfizer says patient died in oral RA drug study
Apr 22, 2011
(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.
Recommended for you
Lateral wedge insoles not associated with improvement of knee pain in osteoarthritis
Aug 20, 2013
Although a pooling of data from 12 studies showed a statistically significant association between use of lateral wedge insoles and lower pain in medial knee osteoarthritis, among trials comparing wedge insoles with neutral ...
New rheumatoid arthritis treatment moves a step closer to reality
Aug 15, 2013
A new rheumatoid arthritis treatment has moved a step closer to reality with the announcement of collaboration between a University of Queensland start-up company and a major pharmaceutical firm.
Eating fish cuts risk of rheumatoid arthritis in women
Aug 13, 2013
(HealthDay)—Regular consumption of dietary long-chain n-3 polyunsaturated fatty acids (PUFAs) in fish is associated with reduced risk of rheumatoid arthritis (RA) in women, according to research published ...
Rheumatoid arthritis heightens risk of dangerous leg and lung blood clots
Aug 07, 2013
Rheumatoid arthritis significantly increases the risk of potentially fatal blood clots in the legs and lungs, reveals a large nationwide study published online in the Annals of the Rheumatic Diseases.
Prolactin reduces arthritis inflammation
Aug 01, 2013
Inflammatory joint diseases such as rheumatoid arthritis are the result of cartilage damage and loss. Chondrocytes are the only cells that are found in cartilage and their death is linked to decreased cartilage health.
Premature aging of immune cells in joints of kids with chronic arthritis
Jul 29, 2013
The joints of children with the most common form of chronic inflammatory arthritis contain immune cells that resemble those of 90-year-olds, according to a new study led by researchers at Children's Hospital of Pittsburgh ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment